Skip to main content
Infection and Immunity logoLink to Infection and Immunity
. 1984 Mar;43(3):795–799. doi: 10.1128/iai.43.3.795-799.1984

Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide.

S J Cryz Jr, E Fürer, R Germanier
PMCID: PMC264250  PMID: 6698608

Abstract

A murine burn wound model was employed to evaluate the relative efficacy of purified Pseudomonas aeruginosa lipopolysaccharide (LPS) and high-molecular-weight polysaccharide as protective immunogens. LPS was found to be both highly immunogenic and protective. As little as three 0.001-microgram doses elicited good immunoglobulin M and G titers and increased the mean lethal dose more than 1,000-fold. The level of protection against a live challenge correlated with antibody titers and was found to be serotype specific. An immunizing regimen which evoked only an immunoglobulin M response was still found to offer substantial protection. Immunization with a high-molecular-weight polysaccharide was also found to be protective. However, approximately 1,000-fold more high-molecular-weight polysaccharide, as compared with LPS, was needed to protect mice to an equivalent degree. Immunization with LPS was found to promote bacterial clearance and prevent establishment of bacteremia. A multivalent LPS vaccine conferred high levels of protection (110- to 53,000-fold) against eight different challenge strains of various serotypes.

Full text

PDF
795

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bjorn M. J., Iglewski B. H., Ives S. K., Sadoff J. C., Vasil M. L. Effect of iron on yields of exotoxin A in cultures of Pseudomonas aeruginosa PA-103. Infect Immun. 1978 Mar;19(3):785–791. doi: 10.1128/iai.19.3.785-791.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bjornson A. B., Michael J. G. Biological Activities of Rabbit Immunoglobulin M and Immunoglobulin G Antibodies to Pseudomonas aeruginosa. Infect Immun. 1970 Oct;2(4):453–461. doi: 10.1128/iai.2.4.453-461.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cryz S. J., Jr, Fürer E., Germanier R. Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. Infect Immun. 1983 May;40(2):659–664. doi: 10.1128/iai.40.2.659-664.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cryz S. J., Jr, Fürer E., Germanier R. Protection against Pseudomonas aeruginosa infection in a murine burn wound sepsis model by passive transfer of antitoxin A, antielastase, and antilipopolysaccharide. Infect Immun. 1983 Mar;39(3):1072–1079. doi: 10.1128/iai.39.3.1072-1079.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Flick M. R., Cluff L. E. Pseudomonas bacteremia. Review of 108 cases. Am J Med. 1976 Apr;60(4):501–508. doi: 10.1016/0002-9343(76)90716-6. [DOI] [PubMed] [Google Scholar]
  6. Holder I. A., Wheeler R., Montie T. C. Flagellar preparations from Pseudomonas aeruginosa: animal protection studies. Infect Immun. 1982 Jan;35(1):276–280. doi: 10.1128/iai.35.1.276-280.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  8. Okada K., Kawaharajo K., Kasai T., Homma J. Y. Effects of somatic component of Pseudomonas aeruginosa on protective immunity in experimental mouse burn infection. Jpn J Exp Med. 1980 Feb;50(1):53–61. [PubMed] [Google Scholar]
  9. Pavlovskis O. R., Edman D. C., Leppla S. H., Wretlind B., Lewis L. R., Martin K. E. Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids. Infect Immun. 1981 May;32(2):681–689. doi: 10.1128/iai.32.2.681-689.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pennington J. E., Hickey W. F., Blackwood L. L., Arnaut M. A. Active immunization with lipopolysaccharide Pseudomonas antigen for chronic Pseudomonas bronchopneumonia in guinea pigs. J Clin Invest. 1981 Nov;68(5):1140–1148. doi: 10.1172/JCI110358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Pennington J. E., Kuchmy D. Mechanism for pulmonary protection by lipopolysaccharide pseudomonas vaccine. J Infect Dis. 1980 Aug;142(2):191–198. doi: 10.1093/infdis/142.2.191. [DOI] [PubMed] [Google Scholar]
  12. Pennington J. E. Lipopolysaccharide pseudomonas vaccine: efficacy against pulmonary infection with Pseudomonas aeruginosa. J Infect Dis. 1979 Jul;140(1):73–80. doi: 10.1093/infdis/140.1.73. [DOI] [PubMed] [Google Scholar]
  13. Pier G. B. Cross-protection by Pseudomonas aeruginosa polysaccharides. Infect Immun. 1982 Dec;38(3):1117–1122. doi: 10.1128/iai.38.3.1117-1122.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Pier G. B. Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. J Clin Invest. 1982 Feb;69(2):303–308. doi: 10.1172/JCI110453. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Pier G. B., Sidberry H. F., Sadoff J. C. High-molecular-weight polysaccharide antigen from Pseudomonas aeruginosa immunotype 2. Infect Immun. 1981 Nov;34(2):461–468. doi: 10.1128/iai.34.2.461-468.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Pier G. B., Sidberry H. F., Sadoff J. C. Protective immunity induced in mice by immunization with high-molecular-weight polysaccharide from Pseudomonas aeruginosa. Infect Immun. 1978 Dec;22(3):919–925. doi: 10.1128/iai.22.3.919-925.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Pollack M., Young L. S. Protective activity of antibodies to exotoxin A and lipopolysaccharide at the onset of Pseudomonas aeruginosa septicemia in man. J Clin Invest. 1979 Feb;63(2):276–286. doi: 10.1172/JCI109300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Pruitt B. A., Jr Infections caused by Pseudomonas species in patients with burns and in other surgical patients. J Infect Dis. 1974 Nov;130 (Suppl)(0):S8–13. doi: 10.1093/infdis/130.supplement.s8. [DOI] [PubMed] [Google Scholar]
  19. Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies. Ann Intern Med. 1975 Jun;82(6):819–831. doi: 10.7326/0003-4819-82-6-819. [DOI] [PubMed] [Google Scholar]
  20. Schimpff S. C., Greene W. H., Young V. M., Wiernik P. H. Pseudomonas septicemia: incidence, epidemiology, prevention and therapy in patients with advanced cancer. Eur J Cancer. 1973 Jun;9(6):449–455. doi: 10.1016/0014-2964(73)90110-2. [DOI] [PubMed] [Google Scholar]
  21. Stieritz D. D., Holder I. A. Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: description of a burned mouse model. J Infect Dis. 1975 Jun;131(6):688–691. doi: 10.1093/infdis/131.6.688. [DOI] [PubMed] [Google Scholar]
  22. Walker H. L., McLeod C. G., Jr, Leppla S. H., Mason A. D., Jr Evaluation of Pseudomonas aeruginosa toxin A in experimental rat burn wound sepsis. Infect Immun. 1979 Sep;25(3):828–830. doi: 10.1128/iai.25.3.828-830.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Young L. S., Armstrong D. Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. J Infect Dis. 1972 Sep;126(3):257–276. doi: 10.1093/infdis/126.3.257. [DOI] [PubMed] [Google Scholar]
  24. Young L. S. Human immunity to Pseudomonas aeruginosa. II. Relationship between heat-stable opsonins and type-specific lipopolysaccharides. J Infect Dis. 1972 Sep;126(3):277–287. doi: 10.1093/infdis/126.3.277. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES